Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer

Overview

Journal Antibodies (Basel)

Date 2025 Jan 23

PMID 39846613

Authors

Isis Wolf

Susanne Schultze-Seemann

Christian Gratzke

Philipp Wolf

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies for targeted delivery into cancer cells. Upon irradiation with visible light, the photosensitizer dye is activated and induces cancer-specific cell death. In the present article, we describe the PIT of prostate cancer (PC) as a therapeutic option for the targeted treatment of localized prostate cancer.

Methods: We conjugated the silicon phthalocyanine dye WB692-CB2 to recombinant cysteine-modified anti-CD44 and anti-EpCAM antibodies via a maleimide linker and tested the antibody dye conjugates for PIT on PC cells and prostate cancer stem cell (PCSC)-like cells.

Results: The anti-CD44 and anti-EpCAM antibody dye conjugates showed specific binding and high cytotoxicity against PC and PCSC-like cells following irradiation with red light. Combined treatment with both conjugates led to enhanced cytotoxic effects.

Conclusions: PIT with our dye WB692-CB2 can serve as an effective focal therapy against prostate cancer, preserving the prostate gland and minimizing side effects. It can be employed during radical prostatectomy (RP) to treat residual tumor cells or lymph node metastases in areas where further surgical intervention is not feasible. Utilizing multiple conjugates against antigens expressed on differentiated PC and PCSC-like cells, such as CD44 and EpCAM, could be an effective method to eradicate residual cancer cells in heterogeneous tumors. This approach could reduce the risk of local recurrence after RP and thus increase the therapeutic outcome of PC patients.

References

Ash C, Dubec M, Donne K, Bashford T . Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017; 32(8):1909-1918. PMC: 5653719. DOI: 10.1007/s10103-017-2317-4. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Marusyk A, Polyak K . Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2009; 1805(1):105-17. PMC: 2814927. DOI: 10.1016/j.bbcan.2009.11.002. View

Rebello R, Oing C, Knudsen K, Loeb S, Johnson D, Reiter R . Prostate cancer. Nat Rev Dis Primers. 2021; 7(1):9. DOI: 10.1038/s41572-020-00243-0. View

Haffner M, Zwart W, Roudier M, True L, Nelson W, Epstein J . Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2020; 18(2):79-92. PMC: 7969494. DOI: 10.1038/s41585-020-00400-w. View

Karantanos T, Corn P, Thompson T . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-11. PMC: 3908870. DOI: 10.1038/onc.2013.206. View

Hou J, Hsu J, Hung M . Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Mol Cell. 2021; 81(22):4579-4590. PMC: 8604761. DOI: 10.1016/j.molcel.2021.09.003. View

Thurber G, Weissleder R . Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol. 2010; 13(4):623-32. PMC: 3000888. DOI: 10.1007/s11307-010-0397-7. View

Wolf I, Gratzke C, Wolf P . Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies. Front Oncol. 2022; 12:935715. PMC: 9304860. DOI: 10.3389/fonc.2022.935715. View

10.

Hsu M, Okamura S, De Magalhaes Filho C, Bergeron D, Rodriguez A, West M . Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model. Cancer Immunol Immunother. 2022; 72(1):151-168. DOI: 10.1007/s00262-022-03239-9. View

11.

Lee Y, Jin J, Cheng C, Huang C, Song J, Huang M . Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013; 11(4):405-17. PMC: 3631285. DOI: 10.1158/1541-7786.MCR-12-0551. View

12.

Wolf I, Storz J, Schultze-Seemann S, Esser P, Martin S, Lauw S . A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy. Bioact Mater. 2024; 41:537-552. PMC: 11378935. DOI: 10.1016/j.bioactmat.2024.07.025. View

13.

Kato T, Okada R, Furusawa A, Inagaki F, Wakiyama H, Furumoto H . Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021; 20(11):2262-2273. PMC: 10214494. DOI: 10.1158/1535-7163.MCT-21-0470. View

14.

Steinwand M, Droste P, Frenzel A, Hust M, Dubel S, Schirrmann T . The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs. 2013; 6(1):204-18. PMC: 3929444. DOI: 10.4161/mabs.27227. View

15.

Botchkina G, Zuniga E, Rowehl R, Park R, Bhalla R, Bialkowska A . Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS One. 2013; 8(9):e69884. PMC: 3782470. DOI: 10.1371/journal.pone.0069884. View

16.

Proietto M, Crippa M, Damiani C, Pasquale V, Sacco E, Vanoni M . Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023; 13:1164535. PMC: 10175698. DOI: 10.3389/fonc.2023.1164535. View

17.

Ward J, Moul J . Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2006; 2(4):174-82. DOI: 10.1038/ncpuro0145. View

18.

Mohiuddin T, Zhang C, Sheng W, Al-Rawe M, Zeppernick F, Meinhold-Heerlein I . Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy. Int J Mol Sci. 2023; 24(3). PMC: 9916513. DOI: 10.3390/ijms24032655. View

19.

James N, Tannock I, Ndow J, Feng F, Gillessen S, Ali S . The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024; 403(10437):1683-1722. PMC: 7617369. DOI: 10.1016/S0140-6736(24)00651-2. View

20.

Ge R, Wang Z, Cheng L . Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol. 2022; 6(1):31. PMC: 9068628. DOI: 10.1038/s41698-022-00272-w. View